View Financial HealthIndivior Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Indivior Pharmaceuticals現在配当金を支払っていません。主要情報0%配当利回り3.2%バイバック利回り総株主利回り3.2%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.Jul 27Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.Nov 18すべての更新を表示Recent updatesIndivior Surpasses Q1 Forecasts as SUBLOCADE Drives Growth and Guidance Rises May 04Indivior Pharmaceuticals, Inc. Raises Earnings Guidance for the Fiscal Year 2026May 02Indivior Pharmaceuticals, Inc. to Report Q1, 2026 Results on Apr 30, 2026Apr 10Indivior Pharmaceuticals, Inc. Announces Findings From Cost Impact Model For Monthly Injectable BuprenorphineMar 31Indivior Pharmaceuticals, Inc., Annual General Meeting, May 13, 2026Mar 30Indivior Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full-Year 2026Feb 26Indivior Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 26, 2026Jan 28+ 1 more updateIndivior PLC Provides Earnings Guidance for the Full Year 2026Jan 08Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable BuprenorphineNov 04Indivior PLC Raises Earnings Guidance for the Year 2025Oct 30Indivior PLC to Report Q3, 2025 Results on Oct 30, 2025Oct 17Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network OpenOct 15Indivior Proposes New Corporate Structure to Achieve U.S. DomiciliationOct 01Indivior's Strategic Turnaround Gains Traction Post-Q2 2025 Aug 05Indivior PLC Revises Earnings Guidance for the Year 2025Jul 31Indivior Announces Completion of Cancellation of Secondary Listing on London Stock ExchangeJul 25Indivior PLC Announces Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use DisorderJul 23Indivior PLC to Report Q2, 2025 Results on Jul 31, 2025Jul 17Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025Jul 08Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025Jun 25Indivior PLC Presents New Data at CPDD Demonstrating That High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl UsersJun 19Indivior Intends to Cancel LSE ListingJun 03High number of new directors Jun 01Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through Ind Enabling StudiesMay 12Indivior: Trying To Break Addiction Apr 28New major risk - Negative shareholders equity Apr 25First quarter 2025 earnings: EPS and revenues exceed analyst expectations Apr 25Indivior PLC, Annual General Meeting, May 08, 2025Mar 31Indivior PLC Announces Appointment of Joe Ciaffoni as Chief Executive OfficerMar 05Indivior PLC Announces Board and Board Committee ChangesMar 04Independent Non-Executive Director recently bought US$504k worth of stock Mar 02Indivior PLC Announces Stepping Down of Mark Crossley as Chief Executive OfficerFeb 27+ 1 more updateIndivior Announces FDA Approval of Label Changes for SUBLOCADE (Buprenorphine Extended-Release) InjectionFeb 26Indivior plc Provides Revenue Guidance for the Year 2025Feb 22Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 20Indivior PLC Announces Delayed FDA Approval of SUBLOCADE® Label ChangesFeb 12Indivior PLC to Report Q4, 2024 Results on Feb 20, 2025Feb 04Indivior PLC Appoints Daniel A. Ninivaggi to the Board as an Independent Non-Executive DirectorFeb 03Indivior plc Appoints David Wheadon as Chair of the Board and Chair of the Nomination CommitteeJan 29High number of new directors Jan 02Independent Non-Executive Director recently bought US$251k worth of stock Dec 26Indivior PLC Announces Ryan Preblick Steps Down as Chief Financial OfficerDec 17+ 1 more updateIndivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking TreatmentNov 20Jerome Lande to Step Down from the Board of Indivior plcNov 15Oaktree Capital Sends a Letter to Indivior PLCNov 07Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 25Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 Oct 13Indivior PLC Revises Financial Guidance for the Fiscal Year 2024Oct 11+ 1 more updatePrice target decreased by 18% to US$19.33 Oct 10Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority ReviewOct 07Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the BoardOct 04Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use DisorderSep 04Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research CollaborationAug 27Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain OfficersAug 03Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 28Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.Jul 27Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback Jul 26Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024Jul 09+ 2 more updatesIndivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)Jun 24+ 4 more updatesIndivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory DepressionJun 19Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use DisorderJun 13Indivior plc Reaffirms Revenue Guidance for the Year 2024May 25Indivior PLC Announces Board Committee ChangesMay 11Indivior plc Reconfirms Earnings Guidance for 2024Apr 27First quarter 2024 earnings: EPS and revenues miss analyst expectations Apr 25Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024Mar 22Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024Mar 21+ 3 more updatesCEO & Executive Director recently sold US$1.9m worth of stock Mar 20Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal NaloxoneMar 12New minor risk - Insider selling Mar 08Chief Human Resources Officer recently sold US$2.3m worth of stock Mar 08Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 23Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024Jan 20Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.Nov 18Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023Nov 11Third quarter 2023 earnings: EPS misses analyst expectations Nov 10Indivior PLC Announces Executive ChangesNov 09Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023Oct 24Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023Oct 06Two Seas Capital Provides Information to Shareholders of Indivior PLCOct 05Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023Oct 01Indivior PLC Revises Earnings Guidance for the Year 2023Jul 29Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022) Jul 28Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023Jun 29High number of new directors Jun 13決済の安定と成長配当データの取得安定した配当: INDVの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: INDVの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Indivior Pharmaceuticals 配当利回り対市場INDV 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (INDV)0%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (INDV) (最長3年)0%注目すべき配当: INDVは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: INDVは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: INDV US市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: INDVが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 19:32終値2026/05/01 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Indivior Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Graham Glyn ParryBofA Global ResearchChase KnickerbockerCraig-Hallum Capital Group LLCBrandon FolkesH.C. Wainwright & Co.6 その他のアナリストを表示
Indivior Pharmaceuticals, Inc. Announces Findings From Cost Impact Model For Monthly Injectable BuprenorphineMar 31
Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable BuprenorphineNov 04
Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network OpenOct 15
Indivior PLC Announces Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use DisorderJul 23
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025Jul 08
Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025Jun 25
Indivior PLC Presents New Data at CPDD Demonstrating That High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl UsersJun 19
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through Ind Enabling StudiesMay 12
Indivior PLC Announces Stepping Down of Mark Crossley as Chief Executive OfficerFeb 27+ 1 more update
Indivior Announces FDA Approval of Label Changes for SUBLOCADE (Buprenorphine Extended-Release) InjectionFeb 26
Indivior PLC Appoints Daniel A. Ninivaggi to the Board as an Independent Non-Executive DirectorFeb 03
Indivior plc Appoints David Wheadon as Chair of the Board and Chair of the Nomination CommitteeJan 29
Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking TreatmentNov 20
Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority ReviewOct 07
Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use DisorderSep 04
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research CollaborationAug 27
Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain OfficersAug 03
Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)Jun 24+ 4 more updates
Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory DepressionJun 19
Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use DisorderJun 13
Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024Mar 22
Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal NaloxoneMar 12
Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023Oct 01